| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214684 | ORGANON | Methods for the treatment of allergic rhinitis |
Dec, 2014
(9 years ago) | |
| US7214683 | ORGANON | Compositions of descarboethoxyloratadine |
Dec, 2014
(9 years ago) | |
|
US7214683 (Pediatric) | ORGANON | Compositions of descarboethoxyloratadine |
Jun, 2015
(8 years ago) | |
|
US7214684 (Pediatric) | ORGANON | Methods for the treatment of allergic rhinitis |
Jun, 2015
(8 years ago) | |
| US6100274 | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul, 2019
(4 years ago) | |
|
US6100274 (Pediatric) | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan, 2020
(4 years ago) | |
| US7618649 | ORGANON | Extended release oral dosage composition |
Dec, 2020
(3 years ago) | |
|
US7618649 (Pediatric) | ORGANON | Extended release oral dosage composition |
Jun, 2021
(2 years ago) | |
| US7820199 | ORGANON | Stable extended release oral dosage composition |
Mar, 2022
(2 years ago) | |
| US6979463 | ORGANON | Stable extended release oral dosage composition |
Mar, 2022
(2 years ago) | |
|
US7820199 (Pediatric) | ORGANON | Stable extended release oral dosage composition |
Sep, 2022
(1 year, 6 months ago) | |
Clarinex D 24 Hour is owned by Organon.
Clarinex D 24 Hour contains Desloratadine; Pseudoephedrine Sulfate.
Clarinex D 24 Hour has a total of 11 drug patents out of which 11 drug patents have expired.
Expired drug patents of Clarinex D 24 Hour are:
- US7214684
- US7214683
- US7214683*PED
- US7214684*PED
- US6100274
- US6100274*PED
- US7618649
- US7618649*PED
- US7820199
- US6979463
- US7820199*PED
Clarinex D 24 Hour was authorised for market use on 03 March, 2005.
Clarinex D 24 Hour is available in tablet, extended release;oral dosage forms.
Clarinex D 24 Hour can be used as a method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis, treatment of allergic rhinitis.
The generics of Clarinex D 24 Hour are possible to be released after 28 September, 2022.
Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient
Market Authorisation Date: 03 March, 2005
Treatment: Treatment of allergic rhinitis; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis
Dosage: TABLET, EXTENDED RELEASE;ORAL
CLARINEX D 24 HOUR family patents
